APMA News - July/August 2021 - 41

Development Update
Corporate Profiles
Editor's Note: The following is promotional content furnished by the companies featured
Hexima Limited
Hexima is proud to be a new corporate partner of APMA.
We look forward to supporting and being a key provider of
resources for podiatrists in their endeavors to continually
improve the delivery of health care and in so doing, the
quality of life of their patients.
Hexima is a clinical stage, anti-infective focused
biotechnology
company
engaged
in
the
research
and
development of defensin peptides as potential human
therapeutics. Our lead product candidate, pezadeftide,
applied in a topical formulation, demonstrates a novel and
powerful fungicidal mode of action and is a potential new
prescription
treatment
for onychomycosis.
Hexima
is
currently conducting an Australian-based phase IIb clinical
trial testing pezadeftide for the treatment of mild to moderate
onychomycosis. Hexima is preparing to file an IND with the
FDA and conduct Phase lll clinical trials in the US. Hexima
holds granted, long-life patents protecting pezadeftide in
major markets globally.
Hexima's goal is to develop a safe and effective prescription
topical treatment for onychomycosis patients, with a
convenient short course of therapy delivering rapid clearance
of infection. We expect pezadeftide to deliver a superior cure
rate, require a shorter treatment time, and exhibit fewer side
effects than existing oral and topical treatment options.
For further information:
www.hexima.com.au
Michael Aldridge
Managing Director & CEO
m.aldridge@hexima.com.au
KorPathTM
KorPathTM
* ENFD testing
* Extensive IT applications, interfacing MIPS and MACRA
consulting
* Diagnostic and PharmD consulting
* 24-48 hour turnaround time
was founded for the purpose of improving
financial and clinical outcomes for patients encountering
diagnostic services for both anatomical and molecular
pathology. These services are vast and range from accurately
identifying cancers and inflammatory processes to rapidly
diagnosing
pathogens.
KorPathTM
infections
caused
by antibiotic-resistant
One of the most practical ways of reducing these threats to
human health is through the development of the best
diagnostic tools in the marketplace coupled with an
unmatched service and professional team.
In addition to being a full-service anatomical pathology
lab, KorPathTM
has become a pioneer in the development of
customized pathogen panels that identify pathogens
according to their genetic sequence, as well as the resistance
genes they carry, all within 24 hours of specimen arrival to
the laboratory.
KorPathTM
is supported by a full team of PharmDs who
review each infectious disease report and provide a Pharmacy
Guidance Overview based off patient-specific information
and test results. Providers can then make timely and informed
decisions about treatment instead of blindly prescribing
medications that are either unnecessary or ineffective.
www.korpath.com
is a national high-complexity laboratory in
Tampa, FL, providing a full array of services including:
* Full anatomical pathology lab services
* Technical professional component/non-government purchasing
programs
* Immunofluorescence services
* Mobile telepathology frozen section services
* Molecular infectious disease testing
* Antibiotic resistance gene testing
APMA News July/August 2021 41
http://www.hexima.com.au http://www.korpath.com
APMA News - July/August 2021

Table of Contents for the Digital Edition of APMA News - July/August 2021
